Partial
Partially Aligned
Patient Risk:
Medium
Summary
Several safety and dosing concepts align with the label excerpts (e.g., adjunctive partial-onset seizures in patients ≥16, metabolic acidosis/CO2 bicarbonate monitoring, suicidal ideation warning, gradual taper, kidney stone risk, rash/SJS/TEN, and carbonic anhydrase mechanism). However, multiple claims are unsupported or partially mismatched to the provided label text, including omission of the adjunctive indication specificity and age restriction, several administration/formulation mismatches (tablet vs oral suspension, and teaspoon dosing guidance), incomplete/incorrect “urgent care symptom” examples, and inaccurate dosing/titration details (e.g., titration rationale and maximum dose escalation timing/limits).
Category Scores
Accurate Statements
Zonisade is a brand name for zonisamide.
Consistent with ZONISADE (zonisamide) naming in provided label excerpts.
Zonisade is an anti-seizure (anticonvulsant) medicine.
Implied by indication for treatment of partial-onset seizures (Section 1).
Zonisade is used to treat certain seizure disorders.
Indicated for adjunctive therapy for treatment of partial-onset seizures (Section 1).
Zonisade helps control seizures by changing the way nerve cells send signals in the brain.
Mechanism section exists, but label excerpts specify carbonic anhydrase inhibitor mechanism; this statement is directionally about therapeutic effect but not explicitly supported as written.
Zonisade affects ion channels.
Not supported by provided label excerpts; label excerpts state carbonic anhydrase inhibitor (Section 12.1).
Zonisamide can cause metabolic acidosis.
Section 5.8: Zonisamide causes hyperchloremic, non-anion gap metabolic acidosis; Section 12.1/12.2.
Metabolic acidosis with zonisamide is described as a blood chemistry problem that can happen with carbonic anhydrase–related effects.
Section 5.8: caused by inhibitory effect on carbonic anhydrase; described as metabolic acidosis.
Zonisamide can increase the risk of kidney stones.
Section 5.13: may cause kidney stones.
Zonisamide can be associated with suicidal thoughts/behavior.
Section 5.7: AEDs including ZONISADE increase risk of suicidal thoughts or behavior.
Zonisamide should not be stopped abruptly unless a clinician directs it.
Section 2.4: avoid abrupt discontinuation when possible; withdraw gradually.
Some seizure control effects of zonisamide can show up within weeks.
Not supported by provided excerpts.
Consistent daily use is important for zonisamide.
Label states once or twice daily administration; exact “consistent daily use” rationale not explicitly stated.
Zonisade interactions review includes medicines that can affect sedation or cognition.
Section 7.1: concomitant CNS depressants including alcohol may increase risk of CNS depression; label also includes CNS adverse reactions.
Zonisade product labeling can vary by country in strengths, formulation, and exact indications on the package insert.
Not present in provided label excerpts; unsupported.
Unsupported Statements
Zonisade is typically used as part of therapy for people with epilepsy, often as an add-on treatment in clinical practice.
Label excerpt specifies adjunctive therapy for partial-onset seizures but does not support broad claims about “people with epilepsy” or “often as an add-on treatment in clinical practice.”
Zonisade helps control seizures by changing the way nerve cells send signals in the brain.
Provided label excerpts do not describe this specific neural signaling mechanism; they state carbonic anhydrase inhibitor mechanism with contribution unknown (Section 12.1/12.2).
Zonisade affects ion channels.
Not supported by provided label excerpts.
Zonisade is generally supplied in oral tablet form.
Provided label excerpt specifies oral suspension (100 mg/5 mL), not tablets (Section 3).
Common side effects of zonisamide medicines can include sleepiness or dizziness.
Label excerpt lists somnolence and dizziness as common adverse reactions, so this is supported generally; but the statement is phrased as non-label generalization (“can include”) and is not specifically tied to ZONISADE oral suspension vs capsules. Overall, partially supported; flagged as unsupported due to lack of excerpt explicitly tying to suspension formulation.
Common side effects of zonisamide medicines can include headache.
Headache is not listed in the provided common adverse reaction excerpt.
Common side effects of zonisamide medicines can include nausea or loss of appetite.
Label excerpt includes anorexia (loss of appetite) but does not include nausea in the provided common adverse reactions list.
Common side effects of zonisamide medicines can include weight loss.
Weight loss is not explicitly listed in the provided common adverse reaction excerpt.
Common side effects of zonisamide medicines can include tingling or numbness sensations.
Not listed in the provided common adverse reactions excerpt.
Zonisamide can cause severe allergic reactions.
Label excerpts emphasize sulfonamide-related potentially fatal reactions and hypersensitivity/DRESS, but “severe allergic reactions” is vague and not directly stated as such.
Symptoms prompting urgent medical care include worsening confusion.
Provided label excerpt specifies measuring serum ammonia if signs/symptoms of encephalopathy occur, but does not list “worsening confusion” as an urgent-care symptom example.
Symptoms prompting urgent medical care include severe breathing problems.
Not supported by the provided label excerpts.
Symptoms prompting urgent medical care include extreme rash.
Rash/SJS/TEN guidance exists but “extreme rash” as an “urgent medical care” symptom example is not explicitly stated.
Symptoms prompting urgent medical care include signs of kidney stones such as severe flank pain and blood in urine.
Label excerpt notes kidney stones may occur and general fluid/urine output advice; it does not provide these specific symptom descriptors.
People with a history of kidney stones need extra clinician guidance when taking Zonisade.
Label excerpt mentions kidney stones may occur and provides general measures; it does not specify “history of kidney stones” needing extra clinician guidance.
People with metabolic acidosis or kidney disease need extra clinician guidance when taking Zonisade.
Metabolic acidosis monitoring/treatment guidance exists, but “kidney disease” is broader than the provided explicit instruction to avoid in renal failure (GFR < 50).
People taking other medicines that can affect the same pathways need extra clinician guidance when taking Zonisade.
Label provides interaction-specific guidance (CNS depressants, other carbonic anhydrase inhibitors, CYP3A4 inducers) but does not support this generalized “same pathways” wording.
Pregnant or planning pregnancy requires extra clinician guidance when taking Zonisade.
Label provides contraception advice and teratogenicity language, but the statement is not directly supported as phrased (“extra clinician guidance”).
Seizure medicines can affect fetal risk.
Label excerpt specifically discusses Zonisamide fetal harm; it does not support a general statement about “seizure medicines” broadly.
Zonisamide is usually started at a lower dose and increased gradually.
Titration exists, but the statement is generalized and does not match the exact initial dose and incremental schedule provided.
Gradual dose increase is used to reduce side effects and improve tolerability.
Label excerpts do not state this rationale.
Zonisamide should be taken exactly as prescribed.
Not a label excerpt-level instruction.
Some seizure control effects of zonisamide can show up within weeks.
Not supported by provided excerpts.
Dose titration means it may take longer to reach full benefit with zonisamide.
Not supported by provided excerpts.
Zonisade is different from valproate, levetiracetam, carbamazepine, and others in how it works.
Label excerpts do not compare mechanisms vs those drugs.
Zonisade is different from valproate, levetiracetam, carbamazepine, and others in its side-effect profile.
Label excerpts do not compare side-effect profiles vs those drugs.
Patients on Zonisade often need their medication list reviewed for interactions with other anti-seizure drugs and medicines.
Label provides specific interaction categories, but does not state “often need” for anti-seizure drugs broadly.
Zonisade interactions review includes medicines that can affect kidney function and hydration status.
The provided interaction excerpts do not mention hydration status specifically.
Zonisade interactions review includes medicines that can affect blood acidity/metabolic balance.
Not explicitly supported; label states other carbonic anhydrase inhibitors may increase severity of metabolic acidosis and kidney stones.
Zonisade product labeling can vary by country in strengths, formulation, and exact indications on the package insert.
Not present in provided label excerpts.
Contradictions
High
AI Statement
Zonisade is generally supplied in oral tablet form.
Label Reference
Section 3 DOSAGE FORMS AND STRENGTHS: “Oral suspension: 100 mg/5 mL … strawberry flavored liquid.”
Low
AI Statement
Zonisade is used to treat certain seizure disorders.
Label Reference
Section 1 INDICATIONS AND USAGE: indicated as adjunctive therapy for partial-onset seizures in adults and pediatric patients 16 years and older.
Important Omissions
Indication specificity: adjunctive therapy for partial-onset seizures in adults and pediatric patients 16 years and older (age restriction and “adjunctive” are not explicitly stated in the AI claims).
Importance:
Moderate
Dosing schedule details from the label: initial 100 mg daily; increase by 100 mg daily every two weeks to 400 mg daily; possible increase up to 600 mg daily; once or twice daily with or without food; and not exceeding evidence-based suggestion beyond 400 mg/day (clinical trials).
Importance:
Moderate
Contraindication: hypersensitivity to sulfonamides or zonisamide (not mentioned in AI response).
Importance:
Moderate
Safety monitoring for metabolic acidosis: baseline and periodic serum bicarbonate.
Importance:
Moderate
Administration specifics for the oral suspension: shake well before every administration; accurate measuring device (household teaspoon not accurate); discard unused portion 30 days after first opening.
Importance:
Moderate
Renal impairment precaution: avoid use in renal failure (eGFR < 50 mL/min).
Importance:
Moderate
Pregnancy-specific guidance: contraception for women of childbearing potential; fetal malformations risk described.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Contradiction regarding dosage form (tablet vs oral suspension) and multiple unsupported/incorrect symptom and administration/generalization claims could lead to inaccurate use/urgency guidance. Missing label-critical items (adjunctive + age indication specificity, contraindications, monitoring serum bicarbonate, renal failure avoidance, and key suspension measuring/shake/discard instructions) further reduce alignment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Material mismatch on dosage form (tablet vs oral suspension) plus omission of key label specifics (adjunctive indication with age ≥16; contraindications; metabolic acidosis monitoring; renal failure avoidance; and administration/measurement/shake/discard instructions).
Suggested Improvement
Restrict claims to the provided label excerpts: state adjunctive therapy for partial-onset seizures in patients ≥16; specify oral suspension; include contraindication (sulfonamide/zonisamide hypersensitivity); mirror dosing schedule (initial 100 mg daily, titration by 100 mg daily every 2 weeks, once/twice daily with or without food) and administration instructions (shake well; accurate measuring device; discard after 30 days); and include baseline/periodic serum bicarbonate monitoring plus renal failure avoidance (eGFR <50). Remove or qualify unsupported generalizations (ion channels, headache/nausea/weight loss/tingling frequency, specific urgent-care symptom examples not in excerpts, and generalized “extra clinician guidance” statements not explicitly stated).